## Original Article

- Safety and Efficacy of AJG522 as a Bowel Cleansing Agent for Colonoscopy in Healthy Japanese Subjects
  - Hidetoshi FURUIE, et al.
  - Page 53
- Risk Management for Recomodulin: With Special Reference to All-Case Surveillance
  - Katsuhito NIHASHI, et al.
  - Page 61

## Forum

- Performance and Problems of Electronic Remote Source Data Verification: A Pilot Study of Inspection Data Presentation and Questionnaire Survey after Study
  - Morihiro NOMURA, et al.
  - Page 71

## Review Article

- Drug-Drug Interactions of the Oral Spherical Activated Charcoal Kremezin®
  - Tsutomu KOTEGAWA, et al.
  - Page 77

## Proceedings of the 33rd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

- Contents
  - Page 85
- “Achievements and Prospects of Pharmacogenomics (PGx) in Clinical Pharmacology”
  - Page 87
- “Predictive Markers for Clinical Response and Adverse Effects of Selective Serotonin Reuptake Inhibitors”
  - Page 109
- “Ethics in Clinical Trial in Japan: Is It Possible to Solve Double Standards?”
  - Page 127
- “Towards the Establishment of Formal Regulatory System of Compassionate Use of Drugs in Japan”
  - Page 149
- “Biobanks of Genes and Tissues and Digitization of All Medical Records”
  - Page 171

## Report

- Report of Trainee of the Foreign Clinical Pharmacology Training Program: No.1
  - Wakako NAKANO
  - Page 181

## Book Review

- Toshihiro HAMA
  - Page 108

## Drug Information

- Information for Authors
  - Page 43E

## Announcements

- Page 45E
# Contents of Proceedings of the 33rd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

**Preface**

**Achievements and Prospects of Pharmacogenomics (PGx) in Clinical Pharmacology**

1. Exploratory Studies of Genetic Markers for Drug Adverse Reactions by GWAS Approaches
   - Kouichi KUROSE, et al.
   - Page: 89

2. Application of PGx for Prevention of Gastric Cancer by Eradication of *H. pylori*
   - Takahisa FURUTA, et al.
   - Page: 95

3. The Situation and Future Prospects of Pharmacogenomics Consortium in Novel Drug Development
   - Akira SHINAGAWA
   - Page: 101

4. Challenges on DNA Sample Collection for Future Use to Promote PGx-Based Medicine
   - Yoshiaki UYAMA
   - Page: 106

**Predictive Markers for Clinical Response and Adverse Effects of Selective Serotonin Reuptake Inhibitors**

1. Biological Markers for Predicting Efficacy and Tolerability in New Antidepressants
   - Reiji YOSHIMURA
   - Page: 110

2. Influence of Pharmacokinetics of SSRI on Clinical Efficacy and Side Effects
   - Takashi WATANABE, et al.
   - Page: 114

3. Prediction of Treatment Response in Depression Based on Genetic Factors from the Practical Viewpoint
   - Masaki KATO
   - Page: 117

4. Determinant Factors of Therapeutic Response to SSRI
   - Norio YASUI-FURUKORI
   - Page: 123

**Ethics in Clinical Trial in Japan: Is It Possible to Solve Double Standards?**

1. Background and Activities of Sub-Committee of Research Ethics, Committee of Academic Affairs, the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)
   - Kiichiro TSUTANI
   - Page: 127

2. Regulations of Clinical Research in Japan: An Historical Overview
   - Shimon TASHIRO
   - Page: 131

3. The Double Standard of Institutional Review in University Hospital, Whether the Clinical Trials Aim at Approval or Not
   - Ryuji KOIKE
   - Page: 136

4. The Past and Future of Ethical Guidelines for Clinical Studies
   - Noriko MORISHITA
   - Page: 141

5. Ethical Review of Human Studies in Japan
   - Toshiyuki SASAGURI
   - Page: 145

**Towards the Establishment of Formal Regulatory System of Compassionate Use of Drugs in Japan**

1. Compassionate Use: Concept, Present Status in the World, and Challenge for Japan
   - Akio TERAOKA, et al.
   - Page: 149

2. Pharmaceutical Industry’s Views on Compassionate Use of Medicinal Products (Access to Unapproved Drugs)
   - Masaaki KUWAHARA
   - Page: 157

3. The Expanded Access Program in Japan
   - Toshio MIYATA
   - Page: 161

4. Legal Issues on Compassionate Use – Toward a Legal Theory Construction that Enables Suitable Responses to the Needs When Necessary--
   - Tetsu ISOBE
   - Page: 167

**Biobanks of Genes and Tissues and Digitization of All Medical Records**

1. Utilization of the Clinical Information for Pharmacoepidemiology
   - Yayoi NISHIDA, et al.
   - Page: 173

2. The Challenge of Tohoku Medical Megabank Organization for Drug Developing through the Genomic Cohort in Disaster Area of East Japan Earthquake
   - Hideyasu KIYOMOTO
   - Page: 175

3. Banking System and the Research Use of Human Tissue at Academia
   - Sachiko TAKENOSHI-TAKAYA, et al.
   - Page: 177

4. Ethical and Legal Ramifications of Biobanks and Health Information Databases
   - Eiji MARUYAMA
   - Page: 179